Signal from the log
InduPro
77 M$ · Series B · United States
Biotechnologie de Seattle et Cambridge qui cartographie la position relative des protéines de membrane, pour en tirer des cibles que la seule liste des protéines présentes ne donne pas. Son premier candidat, IDP-001, est un conjugué anticorps-médicament bispécifique dirigé contre EGFR et un antigène de proximité, entré en phase 1 dans le cancer du poumon non à petites cellules.
Verified
Announced on , logged by the watch of 12 August 2026.
- Operation
- Funding round
- Announced amount
- 77 M$
- Stage
- Series B
- Country
- United States
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by The Column Group , with Vida Ventures , MRL Ventures Fund , Emerson Collective , Euclidean Capital , Solasta Ventures , Sanofi , Eli Lilly and Company
Provenance
Source fierce tracker
Logged on 12 August 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.